Thus, based on our previous investigations and the present study, we propose a new strategy for personalized cell-mediated gene therapy for stroke treatment based on the intravenous infusion of the autologous GEL temporally secreting neuroprotective factors (VEGF, GDNF, and NCAM). This evidence concerns the gene VEGFA and stroke disorder.